Abbott Laboratories stock gets Barclays coverage at USD 120 target

Published on 10/07/2026 at 17:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Abbott Laboratories stock was trading at USD 97.89 on October 7, 2026, within a USD 81.97 to USD 135.13 yearly span. Q2 revenue reached USD 12.593 billion, up 13.0 percent.

Bauhaus MEDTECH DIAGNOSTIK Abbott Laboratories US0028241000 — Abbott Laboratories US0028241000 Bauhaus-Poster MEDTECH DIAGNOSTIK Geometrie Primärfarben Rot Gelb Blau Schwarz Kreise Dreiecke, Illustration mit AI erstellt.

Abbott Laboratories stock (ISIN US0028241000) was trading at USD 97.89 on the NYSE at 11:10 a.m. ET on October 7, 2026, giving the company a market capitalization of USD 169.4 billion. MarketBeat reported on October 7, 2026, that Barclays started coverage with an Overweight rating and a USD 120.00 price target.

Barclays starts coverage

The Barclays target lies 22.58 percent above the USD 97.89 price. The target is an analyst view rather than company guidance, but its timing gives the stock a fresh Wall Street reference after the company entered October with its next quarterly report scheduled for October 21.

The broader analyst picture is also constructive. According to MarketBeat, 3 analysts rate Abbott Strong Buy, 21 rate it Buy and 4 rate it Hold, producing a Moderate Buy consensus and an average price target of USD 118.88. That consensus target lies 21.44 percent above the current price.

Revenue growth meets pressure

Abbott's latest reported quarter ended June 30, 2026. Abbott Laboratories reported second-quarter revenue of USD 12.593 billion, up 13.0 percent from the year-earlier quarter, while adjusted diluted EPS rose to USD 1.31 from USD 1.26.

The mix was uneven. Diagnostics revenue increased 42.3 percent on a reported basis, and Medical Devices revenue rose 9.0 percent, while Nutrition revenue fell 3.1 percent. Abbott's full-year 2026 adjusted EPS guidance stood at USD 5.45 to USD 5.60, compared with the previous range of USD 5.38 to USD 5.58.

The next scheduled checkpoint is October 21, 2026. Stock Titan reported that Abbott will publish third-quarter results before the market opens on that date, followed by an earnings call.

Stock remains below yearly high

At USD 97.89 on October 7, 2026, Abbott was 27.56 percent below its 52-week high of USD 135.13 and USD 15.92 above its 52-week low of USD 81.97. The market is therefore weighing Barclays' USD 120.00 target against a share price still below its yearly peak.